Formulation and Characterization of Ethosomal Formulation of Ciclopirox olamine

The goal of the current investigation is to evaluate the transdermal potential of novel vesicular carrier, ethosomes, bearing Ciclopirox olamine an antifungal having limited transdermal permeation. Ciclopirox olamine loaded ethosomes were prepared, optimized and characterized for vesicular shape and surface morphology, vesicular size, size distribution, vesicles skin interaction and stability. The ethosomal formulation (E9) having 3% phospholipids content and 45% ethanol showing the greatest entrapment (72.81 ±3.5%) and size range (152 ±11) was selected for further transdermal permeation studies. Stability study was performed for 120 days, which revealed low aggregation and growth in vesicular size (8.5 ±0.9%). The formulation retained its permeation power after storage. Vesicle skin interaction study also showed that there was no interaction between the formulation and rat skin. Furthermore ethosomal delivery system could be considered for the treatment of number of dermal infections with better efficiency.